Current data suggest that the majority of bladder cancers may be highly dependent on ERK 25, while both FGFR3 mutations and PIK3CA mutations commonly cooccur in NMIBC, suggesting synergistic activation of MAPK and PI3K pathways 26, 27. This evidence concerns the gene FGFR3 and urinary bladder cancer.